Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
Investor's Business Daily on MSN1h
Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 OutlookEli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.
The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...
As the number of people with diabetes and pre-diabetes surges in the UK, we take a look at how to reverse the condition.
Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback